Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients by Djuzenova, C et al.
Normal expression of DNA repair proteins, hMre11, Rad50 and
Rad51 but protracted formation of Rad50 containing foci in
X-irradiated skin fibroblasts from radiosensitive cancer patients
C Djuzenova*,1,BM u ¨hl
1, R Schakowski
1, U Oppitz
1 and M Flentje
1
1Klinik fu ¨r Strahlentherapie der Universita ¨t Wu ¨rzburg, Josef-Schneider-Strasse 11, D-97080 Wu ¨rzburg, Germany
About 5% of oncology patients treated by radiation therapy develop acute or late radiotoxic effects whose molecular mechanisms
remain poorly understood. In this study, we evaluated the potential role of DNA repair proteins in the hypersensitivity of cancer
patients to radiation therapy. The expression levels and focal nuclear distribution of DNA repair proteins, hMre11, Rad50 and Rad51
were investigated in skin fibroblasts strains derived from cancer patients with adverse early skin reaction to radiotherapy using
Western blot and foci immunofluorescence techniques, respectively. Cells from cancer patients with normal reaction to radiotherapy
as well as cells from apparently healthy subjects served as controls. Cellular radiosensitivity after in vitro irradiation was assessed by the
clonogenic survival assay. The clonogenic survival assay and Western blot analysis of the DNA repair proteins did not reveal any
abnormalities in cellular radiosensitivity in vitro and in protein expression levels or their migration patterns in the fibroblasts derived
from cancer patients with hypersensitive reaction to radiotherapy. In contrast, in vitro irradiated cells from radiosensitive patients
exhibited a significantly higher number of nuclei with focally concentrated Rad50 protein than in both control groups. The observed
alteration of the distribution of radiation-induced Rad50 foci in cells derived from cancer patients with acute side reactions to
radiotherapy might contribute to their radiation therapy outcome. These data suggest the usefulness of the Rad50 foci analysis for
predicting clinical response of cancer patients to radiotherapy.
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The reaction of healthy tissue to ionising radiation (IR) is one of
the major factors determining the radiotherapy (RT) schedule and
outcome. During or after RT, up to 5% of cancer patients (Norman
et al, 1988) develop either acute radiotoxic responses, such as
erythema and desquamation of the exposed skin as well as mucosa,
or late adverse reactions, such as fibrosis and telangiectasias. So
the doses of radiation used clinically have been determined on the
basis of an ‘acceptable’ level of adverse skin reactions in 5% of
patients.
There is a large body of evidence in the literature suggesting a
genetic basis for the predisposition to side effects of RT in healthy
tissue (McKay and Peters, 1997). Thus, dysfunction of genes and
their protein products involved in the recognition and processing
of the cellular radiation damage could be a possible molecular
basis underlying the adverse radiotoxic reactions in healthy tissue.
Despite many clinical and experimental efforts, including screen-
ing of the candidate radiosensitivity genes for mutations (Appleby
et al, 1997; Oppitz et al, 1999), screening for abnormalities in key
candidate proteins (Carlomagno et al, 2000; Leong et al, 2003),
functional genomics using DNA-microarrays (Kitahara et al,
2002), induction of DNA double-strand breaks (DSBs) (El-Awady
et al, 2003), the molecular mechanisms of clinical radiosensitivity
remain poorly understood.
DNA double-strand breaks are biologically the most important
lesions produced by IR and other exogenous agents, and they are
the major threats to the genomic integrity of cells (Kanaar et al,
1998). If insufficiently repaired or misrepaired, DSBs may lead to
chromosome breaks, deletions and translocations (Dasika et al,
1999). There are at least two distinct pathways for DSBs repair in
eucaryotic cells. These are the error-prone nonhomologous end-
joining (NHEJ) and error-free homologous recombination (HR)
(Dasika et al, 1999). Until recently, the NHEJ mechanism, which
includes the Ku heterodimer (Ku70 and Ku80), XRCC4 and DNA
ligase IV (for a review, see Jeggo, 1998), was thought to be the
primary mechanism in mammalian cells for repairing DSBs (Jeggo,
1998; Thompson and Schild, 2001). However, accumulating
experimental evidence indicates that the HR pathway is equally
important (Liang et al, 1998; Takata et al, 1998). The relative
contribution of NHEJ and HR varies during cell differentiation and
is also dependent on the cell cycle stage. The NHEJ pathway plays a
dominant role in repairing the g-radiation-induced DSBs during
G1 and early S phase, while HR preferentially operates in late S and
G2 phase (Takata et al, 1998). The HR mechanism involves
proteins of the Rad52 epistasis group genes (Rad50, RAD51,
Rad52, Rad54, Rad55, Rad57, Rad59, Mre11 and Xrs2) and plays a
crucial role in DSBs repair in higher eucaryotic cells (reviewed in
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yThompson and Schild, 2001). Rad51 is the major strand-transfer
protein in eucaryotic cells and found to interact with many
proteins, including c-Ab1, BRCA2, BLM, XRCC3, etc.
An intact Rad50–Mre11–NBS1 complex has been found to be
essential for the normal DSBs repair (Petrini, 1999). Moreover, this
complex participates in both DSBs repair pathways, even though
they are mechanistically different. Recently, mutations in the
Mre11 gene have been identified in four patients from two families
with an ‘ataxia telangiectasia-like disorder’ (ATLD) (Stewart et al,
1999). Although the cellular ATLD phenotype is similar to that of
real ataxia telangiectasia cells, the ATLD mutant cells show lower
radiation sensitivity. Disruption of the mammalian Rad50 gene
results in embryonic cell lethality and increased sensitivity to IR of
explanted blastocytes (Luo et al, 1999). Thus, all embryo
outgrowths containing mutation in mRad50 had lost their inner
cell masses after 2Gy of g-irradiation (Luo et al, 1999).
Prediction of the radiation sensitivity based upon the expression
of Rad51 protein is apparently not straightforward (Vispe ´ et al,
1998; Yanagisawa et al, 1998; Yanez and Porter, 1999; Kim et al,
2001). Some authors have reported that an overexpression of this
protein correlates with the increased cellular resistance against
radiation (Vispe ´ et al, 1998; Yanagisawa et al, 1998; Yanez and
Porter, 1999). In contrast, other workers (e.g. Kim et al, 2001) have
found that overexpression of human Rad51 in CHO cells reduces
the repair of DSBs by homologous recombination.
In order to elucidate the molecular mechanisms underlying
the increased clinical radiosensitivity, the DSBs repair proteins
were analysed in the present study in fibroblast lines de-
rived from patients with different reactions to RT. Owing to
their involvement in both known DSBs repair pathways (NHEJ
and HR), proteins hMre11 and Rad50 were selected as the
promising molecular markers for screening abnormalities in
the cellular radiation response. In addition, we choose Rad51
protein which is involved in HR. Using the Western blot and foci
immunofluorescence techniques, the expression levels, electro-
phoretic migration patterns and subnuclear distributions of the
three proteins were analysed in cells from cancer patients with
increased and normal clinical radiosensitivity, as well as from
healthy donors.
MATERIAL AND METHODS
Materials
Cell culture media, fetal bovine serum (FBS) and most chemicals
were obtained from Sigma (Deisenhofen, Germany). If otherwise
not stated, Falcon plasticware (Becton Dickinson Labware,
Franklin Lakes, NJ, USA) was used in cell culture experiments.
Subjects
The assay was performed on fibroblast strains that were initiated
from skin biopsies of breast cancer patients with normal (grade 0–
1 according RTOG score) and acute (grade 2–4 RTOG, see Table 1)
reaction of their skin to radiotherapy (see Table 1). The study was
approved by the University of Wu ¨rzburg Ethics Committee and all
patients gave informed consent. Skin punch biopsies were
obtained under local anaesthesia from the inner of the upper
arm with a 4mm punch-needle. The biopsy specimens were dis-
aggregated mechanically and primary fibroblast cultures were
initiated by an outgrowth technique in which skin samples were
incubated in complete growth media (see below) in a humidified
atmosphere with 5% CO2 in air at 371C. The outgrowth lasted from
4 to 10 days and the cells were collected until they reach
subconfluence after a mean period of 24 days (range 20–28 days).
Skin fibroblast cultures derived from apparently healthy donors
served as controls. These were: HSF1 and F7 (kindly gifted by
Professor E Dikomey, University Hospital Hamburg-Eppendorf,
Germany), 1BR3 (kindly gifted by Dr P Jeggo, Medical Research
Council, Cell Mutation Unit, University of Sussex, Brighton, UK),
HFIB1 and HFIB2 fibroblast lines were purchased from Cell-Lining
GmbH (Berlin, Germany). Cells at passage from 3 to 12 were used
for experiments.
Culture handling
Monolayer cultures of each strain were grown in Dulbecco’s
modified Eagle’s medium (Sigma D-6046, Deisenhofen, Germany,)
supplemented with 10% FBS (Sigma F-7524), glutamine (1mM)
Table 1 Cloning efficiencies, radiosensitivity parameters of irradiated in vitro skin fibroblasts and grade of early skin reactions to radiotherapy
Strain Clinical description Plating efficiency (%) a (Gy
 1) b (Gy
 2) SF2 RTOG, skin, early
a
1BR3 Normal 14.370.8 0.1770.1 0.0670.06 0.56 —
HFIB1 Normal 36.873.6 0.1470.1 0.0870.02 0.55 —
HSF1 Normal 12.375.1 0.2770.08 0.0570.02 0.48 —
F7 Normal 10.772.1 0.2770.06 0.0670.02 0.46 —
HFIB2 Normal 29.876.8 0.4170.03 0.0570.005 0.37 —
87HF Breast cancer 7.471.0 0.3770.04 0.0370.001 0.42 1
88HF Breast cancer 21.570.8 0.5170.05 0.0570.01 0.30 1–2
89HF Breast cancer 22.070.3 0.4570.04 0.0370.01 0.36 1
94HF Breast cancer 12.971.5 0.3470.03 0.0570.01 0.42 1
98HF Breast cancer 20.173.1 0.6370.06 0.0270.012 0.27 1
121HF Breast cancer 12.872.5 0.5570.22 0.0870.08 0.24 1
HS5 Breast cancer 16.073.0 0.5870.05 0.0570.02 0.26 2–3
HS6 Breast cancer 10.071.0 0.4470.04 0.0370.01 0.38 3
HS8 Breast cancer 11.572.1 0.3570.02 0.0670.006 0.40 3–4
HS13 Breast cancer 24.871.7 0.3870.02 0.0570.005 0.39 3
HS14 Breast cancer 11.871.9 0.4370.02 0.0470.004 0.36 3
HS15 Breast cancer 17.071.6 0.3670.01 0.0470.003 0.41 3
144 Breast cancer 17.271.8 0.7170.04 0.0570.01 0.20 2–3
148 Breast cancer 15.571.6 0.7570.19 0.0370.03 0.20 2
Mean (7s.e.) from at least two independent experiments.
aEarly skin reaction according RTOG score (Cox et al, 1995). RTOG grade: 1 – follicular, faint or dull erythema, dry
desquamation; 2 – tender or bright erythema, patchy moist desquamation, moderate edema; 3 – confluent, moist desquamation, pitting edema; 4 – ulceration, haemorrhage,
necrosis.
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 1 and 100mgml
 1, respec-
tively), hereafter denoted as complete growth medium (CGM).
Cultures were routinely incubated at 371C in a humidified
atmosphere enriched with 9% CO2. The cells that reached
confluence after 2–4 days of incubation were passaged by mild
trypsinisation (0.05% trypsin/0.02% EDTA, Sigma T-3924).
Antibodies
Primary antibodies used were: rabbit polyclonal anti-Rad51
(1:100, Oncogene, PC130) and anti-hMre11 (1:100, Oncogene,
PC388) and mouse monoclonal anti-Rad50 (1:1000, Abcam,
ab145). Secondary species-specific antibodies were either labelled
with horseradish-peroxidase (1:2000, DAKO, Hamburg, Germany)
or with Alexa Fluor 488 and 568nm (1:200, Molecular Probes,
Eugene, OR, USA, A-11001 and A-11011) for Western blot and foci
immunofluorescence detection, respectively.
X-ray irradiation
Irradiation was performed at room temperature using a 6MV
Siemens linear accelerator (Siemens, Concord, CA, USA) at a dose
rate of 2Gymin
 1. After irradiation, cells were recovered in CGM
for the indicated time until harvested.
X-irradiation and colony survival
Cell survival curves were generated by a standard colony-
formation assay as previously described (Djuzenova and Flentje,
2002) with minor modifications. Precooled fibroblasts irradiated
by graded single doses (0–8Gy) were seeded in Petri dishes and
cultivated in CGM. Three replicates were carried out for each
exposure point, and the experiments were repeated at least twice.
After 2 weeks, the cells were fixed and stained with crystal violet.
Colonies of at least 50 cells were scored as survivors. The mean
survival data for each individual cell line were fitted to the linear
quadratic (LQ) model:
SF ¼ expð aX   bX2Þ; ð1Þ
where, SF is the survival fraction, X is the irradiation dose, a and b
are the fitted parameters.
Western blot analysis
Nearly confluent nonirradiated and irradiated with 8Gy fibroblasts
were detached by trypsinisation, lyzed in RIPA buffer (10mM tris-
HCl, pH 7.4, 150mM NaCl, 1% sodium deoxycholate, 1% Triton X-
100) containing protease inhibitors (2mgml
 1 aprotinin, 2mgml
 1
leupeptin, 5mgml
 1 pepstatin, 1mM phenylmethane sulphonyl
fluoride) for 30min on ice and subsequently centrifuged 10min at
500g. Samples equivalent to 20mg of protein were separated using
either 4–12% (for hMre11 and Rad51) or 3–8% (for Rad50)
sodium-dodecyl-sulphate–polyacrylamide precast gels (Invitro-
gen, Karlsruhe, Germany) and transferred to nitrocellulose
membranes according to standard procedures. Equal loading and
transfer were assessed by reprobing the blots with anti-b-actin
antibody (Sigma A-5316) and Ponceau red (Sigma 19976-1),
respectively. b-Actin was used as an internal standard to account
for variations in the amount of protein (usually 20mg) loaded in
each lane. For hMre11, Rad51 or Rad50 detection, membranes
were incubated with respective primary and species-specific
peroxidase-labelled secondary antibodies according to standard
procedures. Protein bands were detected using an enhanced
chemiluminescence system (ECL, Amersham Pharmacia Biotech,
Braunschweig, Germany). The levels of protein expression were
quantified using the Kodak 1D Image analysing software (Scientific
Imaging Systems, Eastman Kodak Company, Rochester, NY, USA)
and normalised to the b-actin levels.
hMre11, Rad51 and Rad50 foci formation
Fibroblasts were cultured on microscope glass slides for at least
24h. Subconfluent cells were irradiated with 8Gy on slides, fixed at
various time points in ice-cold ethanol at  201C, and permeabi-
lised with Triton X-100 (1% solution in PBS) for 5min. Slides were
washed three times for 5min in PBS and blocked in 4% FBS–PBS
for 1h at room temperature. Slides were incubated for 1h at 371C
with anti-hMre11, -Rad50 or -Rad51 primary antibodies, followed
by incubation with respective secondary antibodies conjugated
with Alexa Fluor 488nm or 568nm. Slides were counterstained
with 0.2mgml
 1 of DAPI (40,60-diamidino-2-phenylindole) in
antifade solution (1.5% N-propyl-gallate, 60% glycerol in PBS)
and examined using a Leica DMLB epifluorescence microscope
coupled to a cooled CCD camera (ColorView 12, Olympus
Biosystems, Hamburg, Germany). Camera control and image
acquisition were carried out using an image analysis software
(AnalySis, SoftImaging GmbH, Stuttgart, Germany). For each
experimental point, at least 100 nuclei were examined and hMre11,
Rad51 or Rad50 foci were scored by eye at a magnification of
 1000. Probes were then quantified by counting the number of
foci-positive cells, and also by counting the number of foci per
nucleus in the fraction of foci-positive cells. We used no threshold
for foci number per nucleus.
Statistics
Data are presented as mean (7s.d. or 7s.e.). The mean values
were compared by the Student’s t-test. The threshold of statistical
significance was set at Po0.05. Statistics and fitting of experi-
mental curves were performed with the program Origin (Microcal,
Northampton, MA, USA).
RESULTS
Clonogenic survival
Figure 1 shows the normalised survival responses of the fibroblast
strains averaged through each group as functions of X-ray dose
together with the best fits of the LQ model (Eq. 1). As judged by the
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Figure 1 Survival curves of skin fibroblasts from control donors, cancer
patients with normal reaction to RT and hypersensitive cancer patients as
functions of the radiation dose. Irradiated cell were plated in CGM and
incubated at 371C in a humidified atmosphere with 9% CO2. After 2
weeks, the cells were fixed and stained using crystal violet. Colonies of at
least 50 cells were scored as survivors. The data derived from two
experiments for each strain were pooled together and fitted with a linear-
quadratic equation (Eq. 1). Standard deviations are indicated by error bars.
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ycorrelation coefficients, ranging between 0.97 and 0.99, the LQ
model (curves in Figure 1) provided reasonable approximations to
the experimental data (symbols in Figure 1). Plating efficiencies of
nonirradiated fibroblast strains, as well as the fitted parameters a
and b obtained by the nonlinear regression analysis and the
calculated surviving fractions at 2Gy (SF2) for each individual cell
strain are summarised in Table 1. Judging by the SF2 values,
fibroblasts strains from clinically hypersensitive cancer patients
with SF2¼0.3370.08 (mean7s.d., n¼8) and from cancer
patients with normal clinical sensitivity (SF2¼0.3470.07, n¼6)
were significantly more sensitive to X-irradiation than fibroblasts
from healthy donors (SF2¼0.4870.07, n¼5). However, in this
rather small patient sample there was no difference in the SF2
values between fibroblasts of cancer patients with normal
(SF2¼0.3470.07, n¼6) and hypersensitive (SF2¼0.3370.08)
reactions to RT.
In order to elucidate the cellular mechanisms underlying the
different clinical reactions to RT, we further examined the
expression levels and migration patterns of the three DNA DSBs
repair proteins hMre11, RAd50 and Rad51 as well as their nuclear
focal distribution before and after in vitro irradiation.
Analysis of hMre11, Rad50 and Rad51 by Western blotting
Figure 2 shows a typical Western blot analysis demonstrating the
levels of protein expression in nonirradiated and irradiated with
8Gy fibroblasts. It is obvious from Figure 2 that the expression
levels of all tested proteins were mostly similar in the cells derived
from healthy donors and cancer patients with increased reaction to
RT. Such immunoblots were quantified and the amounts of
hMre11, Rad51 and Rad50 were normalised to the respective levels
of b-actin. Statistical analysis (Figure 3) of the Western blot data
through at least four (up to 12) independent experiments for each
cell line and the group tested revealed that the mean levels of
hMre11 protein were similar in healthy group (1.070.2) and in
group of cancer patient with normal reaction to RT (1.070.1)
before and after (0.770.1 in both groups of subjects) in vitro
irradiation. Cells derived from hypersensitive cancer patients
showed somewhat elevated levels of hMre11 before (1.270.1) and
after (1.070.1) irradiation.
As seen from Figure 3B, the mean basal levels of Rad51 in cells
derived from cancer patients with normal (1.570.4) and
hypersensitive (1.470.1) reaction to RT was higher than that in
cells derived from healthy donors (0.870.1). These differences,
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Figure 2 Western blot analysis of expression levels and migration
patterns of hMre11 (A, top), Rad51 (A, middle) and Rad50 (B, top)
proteins in nonirradiated and irradiated cells from control and radio-
sensitive cancer patients. b-Actin (bottom bands in A and B) was used as
an internal standard to allow for differences in protein loading in each lane
(20mg). There were no differences in expression of hMre11 and Rad51
between control (HFIB1 und F7) and (HS5, HS14, HS8) radiosensitive cell
lines (A), as well as in expression of Rad50 (B) between control (1BR3)
and radiosensitive (HS6, HS8, HS14, HS15) cell lines.
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Figure 3 Expression of hMre11 (top), Rad51 (middle) and Rad50
(bottom) proteins normalised to b-actin before (open symbols) and 2h
after irradiation with 8Gy (solid symbols) assessed by Western blot analysis
of 14 cell lines with different sensitivities to RT and five control cell lines.
Each symbol (except stars) represents the mean value obtained from at
least four independent experiments on the cell strain from a given
individual. Stars represent the mean value (7s.e.) averaged through each
tested group. Western blotting did not reveal any differences in protein
expression between the control group and cancer patients with normal and
increased clinical sensitivity to RT.
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mean level of Rad51 in all cell lines remains similar to that before
irradiation. The mean amounts of the Rad50 protein (Figure 3C,
open symbols) were almost the same in nonirradiated cells derived
from healthy subjects (1.070.2), cancer patients with normal
(0.870.2) and increased clinical reaction (1.070.2). At 2h
postirradiation, the expression of Rad50 decreased by about 20%
in cells from healthy donors and from cancer patients with normal
reaction to RT. In contrast, the irradiated cells of hypersensitive
cancer patients revealed a slightly increased Rad50 level of
1.170.1, which was 1.3 times higher than in irradiated control
cells (0.870.2).
Taken together, the Western blot analysis did not reveal any
significant differences in the net expression of DNA-repair
proteins hMre11, Rad51 and Rad50 between all tested groups.
We therefore further analysed the subnuclear distribution of these
proteins.
hMre11, Rad51 and Rad50 nuclear focus formation
The microphotographs in Figure 4 show the examples of nuclear
foci that appeared in fibroblasts in response to IR, which were
visualised by double immunofluorescence staining for hMre11 (left
images) and Rad50 (middle images). The right-hand images are
merged images. As seen from Figure 4, the brightly fluorescent foci
are clearly distinguishable from the diffuse staining of the
remaining nucleus. Such images were quantified by counting the
number of foci-positive cells, and also by counting the number of
foci per nucleus in the fraction of foci-positive cells.
For hMre11 (Figure 5A) and Rad51 (Figure 5B), analysis of the
fractions of foci-positive cells, as well as of the number of hMre11
and Rad51 foci per nucleus (data not shown) did not reveal any
difference between all tested groups, either before or after
irradiation. In contrast to the hMre11 and Rad51 data, the fraction
of Rad50 foci-positive cells (Figure 5C, filled symbols) in the
irradiated cells from hypersensitive cancer patients (88%) was
significantly higher (o0.005) than in control cells (41%) and cells
from cancer patients with normal reaction to RT (44%). Without
irradiation (Figure 5C, open symbols), the fraction of Rad50 foci-
positive nuclei in the hypersensitive cells (40%) was also
apparently higher than in control (26%) or in cells from cancer
patients with normal reaction to RT (15%). There might be several
reasons for the wide scatter of the data points in Figure 5. Firstly,
we used primary fibroblast strains, which are not monoclonal
lines, but they are rather a heterogeneous population of cells in
different stages of differentiation from fibroblasts to postmitotic
fibrocytes (Bayreuther et al, 1988). Beside this, the cell lines were
in different passage numbers ranging from 3 to 12. Secondly, the
rather small group of patients and the heterogeneity of their
clinical radiation responses may be further important reasons for
the large data variability.
In order to further characterise the observed increase of the
fraction of Rad50 foci-positive nuclei in cells derived from
hypersensitive cancer patients, we quantified the formation of
Rad50 foci by counting their number per nucleus. Figure 6
illustrates typical distributions of Rad50 foci per nucleus in normal
(HFIB1 strain, left-hand column) and hypersensitive cells (HS6
strain, right-hand column). The top, middle and bottom histo-
grams in Figure 6 show the cells without irradition, as well as
30min and 2h after irradiation with 8Gy, respectively. Without
irradiation, the control HFIB1 strain derived from a healthy
subject revealed a substantially larger fraction of Rad50 foci-
negative cells (about 36%) than the hypersensitive HS6 cells (14%).
At 30min postirradiation, the foci-negative fraction in the
hypersensitive HS6 strain disappeared, whereas the control strain
(HFIB1) had a high fraction of foci-negative cells (about 55%). The
Figure 4 Immunofluorescence analysis of nuclear hMre11 and Rad50 foci in irradiated skin fibroblasts derived from a healthy individual (HFIB1, top) and
from a hypersensitive cancer patient (HS5, bottom). Cells were irradiated with 8Gy, fixed 2h postirradiation and double stained with anti-hMre11 (red
fluorescence) and anti-Rad50 (green fluorescence) antibodies. Right-hand images represent merged analysis.
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(about 5) were similar in both strains 30min after irradiation. At
2h after irradiation (Figure 6, bottom histograms), the Rad50 foci-
negative fraction in the control strain remained nearly unchanged
(about 60%), whereas the mean number of foci per nucleus (10)
was twice as high as 30min after irradiation. Compared to the data
of normal cells obtained 2h after irradiation, the hypersensitive
cell line showed a substantially larger fraction of foci-positive cells
(86 vs B40% in control) with a higher number of foci per nucleus
(15 vs 10).
Analysis of the immunofluorescence data (Figures 4–6) revealed
that cells derived from hypersensitive cancer patients differed
markedly in their Rad50 foci forming response to IR from the cells
derived from healthy subjects and cells from cancer patients with
normal clinical reaction to RT.
DISCUSSION
Skin fibroblasts derived from the two groups of cancer patients
were found to be more sensitive to X-irradiation in vitro than cells
from apparently healthy donors when compared by the colony-
forming assay several days or weeks after X-ray exposure (Figure 1
and Table 1). Thus, the mean SF2 value averaged through the
hypersensitive group was significantly lower than in control. At the
same time, the SF2 value for the group of hypersensitive cancer
patients was very similar to that of the group of cancer patients
with normal clinical reaction to RT. This means that in this sample
the in vitro SF2 parameter did not discriminate between normal
and increased acute clinical reactions during and after radio-
therapy. Therefore, other cellular indicators were analysed for their
correlation with the different responses of cancer patients to RT.
As already mentioned, DSBs are the most lethal form of DNA
damage and they also represent the major group of DNA lesions
induced by IR (for a review, see Jeggo, 1998). Therefore, genes
involved in the DSBs processing and repair, such as hMre11, Rad50
and Rad51, might be promising molecular indicators of the
radiation hypersensitivity in vivo. Particularly, identification of
possible alterations in these genes or their proteins could be useful
for predicting hypersensitivity to radiotherapy.
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Figure 5 Percentages of cells containing nuclear foci of hMre11 (top),
Rad51 (middle) and Rad50 (bottom) before (open symbols) and 2h post-
irradiation with 8Gy (solid symbols). Each symbol (except stars) represents
the mean value obtained for 100 cells derived from a given individual, in at
least two independent experiments. Stars represent mean value (7s.e.)
averaged through each tested group. ‘NS’ indicated that the difference was
not highly significant (P40.05).
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Figure 6 Histograms depicting the kinetics of Rad50 focus formation in
normal cells (HFIB1, left column) and cells from a radiosensitive cancer
patient (HS6). Cells were analysed for Rad50 focus induction before (top
histograms), 30min (middle) and 2h (bottom histograms) after irradiation
with 8Gy. In total, 100 nuclei were counted per each time point.
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respect to the clinical radiosensitivity (i.e., grades 1–4 according to
RTOG criteria), an extensive Western blot analysis did not reveal
any differences in the expression and migration patterns of
hMre11 and Rad50 proteins under in vitro conditions (Figures 2
and 3). Assuming that the detected in vitro levels of these proteins
reflect those in vivo, this finding suggests that the net amounts of
these DNA repair proteins do not account for the difference in
radiation response in vivo observed during radiotherapy of these
cancer patients. It should be noted, however, that, firstly, gene
expression analysis based on the protein determination has
obvious limitations mainly due to the constant level of expression
during post-translational modifications. Secondly, due to its poor
accuracy, the Western blot assay may be insufficiently sensitive to
detect subtle differences between the cell lines derived from
patients with different clinical reactions to RT. A poor sensitivity
of Western blot has been pointed out by Carlomagno et al (2000),
who demonstrated that the expression levels of nine different
proteins, and among them Rad51, in 10 cell lines obtained from the
skin biopsies of cancer patients with different clinical radio-
sensitivities were similar to those in three control cell lines. A
recent study (Leong et al, 2003), in which cells from 36 patients
were examined for defects in DNA ligase IV, XRCC4, Ku70 and
Ku80 proteins using Western blot, also did not reveal any
differences in the expression levels and migration patterns for
the four proteins in all tested radiosensitive patients compared
with controls.
In contrast to Carlomagno et al (2000), we observed in the
present study a slight increase in the expression of Rad51 in skin
fibroblasts derived from both groups of cancer patients compared
with healthy group (Figure 3B).
The role of Rad51 protein in radiation sensitivity has been
discussed controversially in the literature. Thus, overexpression of
this protein has been found to correlate with increased cellular
resistance against radiation (Vispe ´ et al, 1998; Yanagisawa et al,
1998; Yanez and Porter, 1999). A 2–3-fold overexpression of
Rad51 in CHO cells has stimulated the homologous recombination
between integrated genes by 20-fold, indicating the key role of this
protein in the intrachromosomal recombination pathway (Vispe ´
et al, 1998). Increased concentrations of the Rad51 mRNA have
also been shown by Northern blot in the radioresistant human KB
carcinoma cell line N10 (Yanagisawa et al, 1998). Three human
prostate cancer cell lines have exhibited increased radiosensitivity
together with significant downregulation of Rad51, as compared to
control cells (Collis et al, 2001). A 2–3-fold increase in
homologous recombination and enhanced resistance to IR has
been reported for cells overexpressing hRAD51 (Yanez and Porter,
1999).
On the contrary, overexpression of human Rad51 in CHO cells
has been found to reduce the repair rate of DSBs by HR (Kim et al,
2001). These authors have also indicated that basal RAD51 gene
expression correlates negatively with micronuclei induction in
irradiated blood cells, and the level of Rad51 can partly explain the
individual sensitivity to IR assessed by radiation-induced micro-
nuclei. A 10-fold overexpression of Rad51 in HT1080 fibrosarcoma
cell line has resulted in decreased plating efficiency and growth
rate, in a dose-dependent manner with regard to the degree of
overexpression (Flygare et al, 2001).
Taken together, the results of this study (Figures 2 and 3) and
the controversial literature quoted above suggest that screening for
abnormalities of DNA repair proteins, hMre11, Rad50 and Rad51,
using Western blotting is unlikely to be useful for predicting
clinical radiosensitivity. Therefore, we extended our experiments
to account for the IR-induced nuclear foci formation of DNA
repair proteins. Indeed, we found a protracted Rad50 foci
formation in irradiated cells derived from cancer patients with
increased early reactions to radiotherapy. Moreover, these cells
displayed also an increased number of Rad50 foci per cell after
irradiation. Our results are in agreement with an earlier report that
the IR-induced foci response is increased for both hMre11 and
Rad50 in a DSB repair-deficient 180BR cell line, which is also
highly sensitive to IR (Maser et al, 1997).
It has been shown previously that IR-induced Rad50 nuclear
focus formation in fibroblast cell lines is independent of the cell
cycle (Yuan et al, 2003). Therefore, the alterations of the Rad50 foci
formation in cells derived from hypersensitive cancer patients
observed in the present study (Figures 4, 5C and 6) cannot be
explained by the differences in the cell cycle distribution between
the cell strains used. The observed increased number and altered
distribution of Rad50 foci suggest a gene defect that impairs the
ability to repair IR-induced DSBs in cells from hypersensitive
cancer patients, thus decreasing the DNA restoration rate in these
cells compared to cells derived from healthy subjects and cancer
patients with normal reaction to RT.
CONCLUSIONS
In this study, the colony-forming assay and Western blot analysis
of the DNA repair proteins hMre11, Rad50 and Rad51 did not
reveal any abnormalities in cellular radiosensitivity in vitro and in
expression levels or migration patters of these proteins in the
fibroblasts derived from the cancer patients with increased early
reaction of normal tissue to radiotherapy. In contrast, the clinical
radiation reaction might correlate with the impaired formation of
the radiation-induced Rad50 foci that was assessed by immuno-
fluorescence microscopy.
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